Verge Genomics and Collaborators Identify Digital Clinical Biomarker Endpoints Sensitive to Short Term Disease Progression in the Pre-treatment Run-in Period of VRG50635 Proof-of-Concept ALS ...

SOUTH SAN FRANCISCO, Calif., April 07, 2025--Verge Genomics, a clinical-stage, tech-enabled biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform ...

Verge Genomics and Collaborators Identify Digital Clinical Biomarker Endpoints Sensitive to Short Term Disease Progression in the Pre-treatment Run-in Period of VRG50635 Proof-of-Concept ALS ...

Verge Genomics (Verge Analytics Inc.) has nominated a second development candidate, VRG-201, targeting long-term weight management and metabolic homeostasis. VRG-201 is an oral, first-in-class ...

— Program is currently in IND-enabling studies and on track to enter the clinic in Q3 2025 SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage ...

— First-in-class, oral small molecule to prevent weight regain, without need for significant lifestyle modifications — Breakthrough potential to treat obesity-related comorbidities by ...

Verge Genomics Announces New Development Candidate, VRG201, a Novel Maintenance Therapy for Long-Term Weight Management Verge Genomics Mon, Dec 16, 2024, 7:00 AM 3 min read ...

Verge Genomics and Eli Lilly expand their ALS collaboration, with Verge's AI-driven CONVERGE® platform identifying therapeutic targets. This milestone triggers milestone payments and potential ...

Verge Genomics, a clinical-stage biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery and development, announced that Eli Lilly & Company ...

Verge Genomics announced that Eli Lilly (LLY) has opted to pursue the development of therapeutics against two validated drug targets for amyotrophic lateral sclerosis, or ALS, as part of the ...

Eli Lilly and Verge Genomics advance ALS drug development with validated targets and a Phase 1B study, part of their $694 million collaboration since 2021.